Thomas F. Hogan
- Hematology top 5%
- Acute Myeloid Leukemia Research 4
- Oncology top 10%
- Cancer Diagnosis and Treatment 3
- Pharmaceutical Science top 5%
- Advanced Drug Delivery Systems 3
- Rheumatology top 10%
-
- Bladder and Urothelial Cancer Treatments 4
-
- Prostate Cancer Treatment and Research 4
-
- Radiopharmaceutical Chemistry and Applications 3
-
- Multiple and Secondary Primary Cancers 3
-
- Lymphoma Diagnosis and Treatment 3
- Co-authors
- Ernest C. BordenJoseph G. VoelkelDuard L. WalkerBillie L. PadgettCheryl L. WillmanTC MeekerStanley J. KandzariC. J. Malanga
- Journals
- Journal of Clinical Oncology (7 papers)Blood (3 papers)Annals of Internal Medicine (1 paper)
- Partner nations
- United StatesChinaUnited Kingdom
In The Last Decade
Thomas F. Hogan
38 papers receiving 1.0k citations
Peers
Comparison fields: 5 of 109
- Hematology 180
- Oncology 391
- Pharmaceutical Science 74
- Rheumatology 132
- Immunology 173
Countries citing papers authored by Thomas F. Hogan
This map shows the geographic impact of Thomas F. Hogan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas F. Hogan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas F. Hogan more than expected).
Fields of papers citing papers by Thomas F. Hogan
This network shows the impact of papers produced by Thomas F. Hogan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas F. Hogan. The network helps show where Thomas F. Hogan may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Thomas F. Hogan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2022 | 2 | |
| 3 | 2022 | 5 | |
| 4 | 2022 | 1 | |
| 5 | 2020 | 7 | |
| 6 | 2020 | 2 | |
| 7 | 2020 | 4 | |
| 8 | 2019 | 7 | |
| 9 | 2012 | 3 | |
| 10 | Malignant paraganglioma of the urinary bladder in a 45-year-old woman. | 2012 | 2 |
| 11 | 2006 | 37 | |
| 12 | Cisplatin, gemcitabine and paclitaxel triplet chemotherapy in 50 patients with advanced or metastatic urothelial cancer. | 2006 | 1 |
| 13 | 2004 | 80 | |
| 14 | 2002 | 4 | |
| 15 | 2002 | 26 | |
| 16 | 1990 | 112 | |
| 17 | 1988 | 9 | |
| 18 | 1986 | 43 | |
| 19 | 1986 | 53 | |
| 20 | The reminiscences of Roger Nash Baldwin | 1975 | 1 |
About Thomas F. Hogan
Thomas F. Hogan is a scholar working on Pharmaceutical Science, Hematology and Oncology, having authored 40 papers that have together received 1.1k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (4 papers), Bladder and Urothelial Cancer Treatments (4 papers), Prostate Cancer Treatment and Research (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers), Advanced Drug Delivery Systems (3 papers), Cancer Diagnosis and Treatment (3 papers), Multiple and Secondary Primary Cancers (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). The work is most often cited by research in Hematology (180 citations), Oncology (391 citations) and Pharmaceutical Science (74 citations). Thomas F. Hogan has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Ernest C. Borden, Joseph G. Voelkel, Duard L. Walker, Billie L. Padgett, Cheryl L. Willman, TC Meeker, Stanley J. Kandzari, C. J. Malanga, Stephen A. Howard and Steven J. Jubelirer. Their work appears in journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.